MOMO'S BREAKOUT BOARD

[BioSpecialist]

RALLYYYYYYYYYYYYY BIG NEWS OUT.....Market cap still at laughable $53 Million

IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the BrainAugust 22, 2016

August 22, 2016


http://www.intelgenx.com/investors/press-releases/press-release-details/2016/IntelGenx-Announces-Successful-Clinical-Study-for-Montelukast-for-the-Treatment-of-Degenerative-Diseases-of-the-Brain/default.aspx


"We are very pleased by the results of the study which confirmed that our Montelukast VersaFilm™ significantly improves the bioavailability of the drug when given as an oral film product. The study demonstrates that the VersaFilm™ technology is an effective delivery system for CNS applications," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "Montelukast is an important drug repurposing opportunity that the company has in its product pipeline which could potentially become a multi-billion-dollar product in the large and underserved market for degenerative diseases of the brain."


NEXT BIG NEWS IS AROUND THE CORNER

Continued late-stage discussions with global pharmaceutical companies for multiple products with the potential goal of concluding a definitive agreement to be finalized in the third quarter of 2016